We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on wallstreetbets Subreddit Page by MostCapital5741. In ...

What Happened? A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.